Humana (NYSE:HUM – Get Free Report) had its target price upped by analysts at Morgan Stanley from $370.00 to $475.00 in a research report issued on Thursday, Benzinga reports. The firm presently has an “equal weight” rating on the insurance provider’s stock. Morgan Stanley‘s price target would suggest a potential upside of 21.80% from the stock’s current price.
A number of other equities analysts also recently weighed in on HUM. Zacks Research upgraded Humana from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 10th. UBS Group raised their price target on shares of Humana from $405.00 to $495.00 and gave the stock a “neutral” rating in a report on Monday, October 12th. JPMorgan Chase & Co. boosted their price objective on shares of Humana from $393.00 to $484.00 and gave the company a “neutral” rating in a research report on Tuesday, November 10th. Leerink Partners raised shares of Humana from a “market perform” rating to an “outperform” rating and set a $513.00 price objective on the stock in a research report on Thursday, July 30th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $420.00 price objective on shares of Humana in a research note on Friday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $491.74.
Get Our Latest Report on Humana
Humana Price Performance
Humana (NYSE:HUM – Get Free Report) last issued its earnings results on Friday, November 6th. The insurance provider reported ($0.70) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.30. Humana had a return on equity of 8.50% and a net margin of 0.81%. The business had revenue of $41.16 billion during the quarter, compared to analysts’ expectations of $40.87 billion. During the same quarter last year, the firm posted $3.24 earnings per share. Humana’s revenue was up 26.1% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.500- EPS. Equities analysts expect that Humana will post 9.59 earnings per share for the current fiscal year.
Insider Buying and Selling at Humana
In other news, insider Joseph Ventura sold 5,495 shares of the firm’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $433.85, for a total transaction of $2,384,005.75. Following the completion of the sale, the insider directly owned 21,910 shares of the company’s stock, valued at $9,505,653.50. This trade represents a 20.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.20% of the stock is owned by company insiders.
Institutional Trading of Humana
A number of institutional investors have recently added to or reduced their stakes in the business. Johnson Financial Group Inc. acquired a new position in shares of Humana in the 2nd quarter valued at $26,000. Trust Co. of Vermont bought a new position in shares of Humana during the 2nd quarter worth about $28,000. Bogart Wealth LLC lifted its holdings in shares of Humana by 192.0% during the 2nd quarter. Bogart Wealth LLC now owns 73 shares of the insurance provider’s stock worth $29,000 after acquiring an additional 48 shares during the period. MidFirst Bank acquired a new stake in shares of Humana during the 2nd quarter valued at about $35,000. Finally, Highland Investment Advisors LLC acquired a new stake in shares of Humana during the 2nd quarter valued at about $43,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.
Top Humana Stories
Here are a few of the latest stories about HUM:
- Neutral Sentiment: Humana is up more than 50% this year, but investors who bought three years ago remain underwater. The durability of the recovery may depend on Medicare Advantage growth, Star Ratings and the company’s December investor update. 247WallSt article
- Negative Sentiment: Zacks Research trimmed its Q3 2028 EPS estimate to $6.38 from $6.58, tempering the positive estimate revisions elsewhere. MarketBeat analyst estimates
- Negative Sentiment: Healthcare insurers came under pressure amid a new Medicare for All proposal. Separately, a proposed CMS anti-fraud rule and a notice of an investigation into Humana’s disclosures around Medicare Advantage audit and repayment risk add policy and regulatory uncertainty. MarketWatch article Benzinga article
About Humana
Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.
Further Reading
- Five stocks we like better than Humana
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
